Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amanat Acquisition Corp.AMAN · Entity 6741 | Director | May 18, 2026 | May 19, 2026 |
| NeuroPace IncNPCE · Entity 5459 | Director | June 19, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amanat Acquisition Corp.
Report date May 18, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | IndirectSee footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2026-05-18 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The reporting person beneficially owns 25,000 Class B ordinary shares which will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading "Description of Securities--Founder Shares and Private Placement Shares" in the Issuer's registration statement on Form S-1 (File No. 333-295170) ("Registration Statement") and have no expiration date. F2: For her services as a director, the Reporting Person receives indirect interest in founder shares through membership interests in the Company's sponsor, Amanat Sponsor Holdings LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person beneficially owns 25,000 Class B ordinary shares which will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading "Description of Securities--Founder Shares and Private Placement Shares" in the Issuer's registration statement on Form S-1 (File No. 333-295170) ("Registration Statement") and have no expiration date.
F2: For her services as a director, the Reporting Person receives indirect interest in founder shares through membership interests in the Company's sponsor, Amanat Sponsor Holdings LLC.
NeuroPace Inc
Report date June 19, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,039 |
Reported balance
After 2026-06-19 transaction · row 1
1 source rowRow 1 · 2026-06-19 · Grant · Acquired 989 · Balance 23,039 F1: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Roivant Sciences Ltd.
Report date February 20, 2025 · Filed February 25, 2025
Section 16 reporting ended · disclosed 2025-02-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 162,306 |
Reported balance
After 2025-02-20 transaction · row 1
1 source rowRow 1 · 2025-02-20 · Tax withholding · Disposed 958 · Balance 162,306 F1: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 23, 2022 Filed Dec 29, 2022 02:31 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 1,592 | $7.10 | $11,303.20 |
DisclosureSEC source: 0001140361-22-047270 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,178 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| November 20, 2022 Filed Nov 22, 2022 23:33 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 1,584 | $5.00 | $7,920.00 |
DisclosureSEC source: 0001140361-22-042831 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,770 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| October 25, 2022 Filed Oct 27, 2022 22:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 1,588 | $4.40 | $6,987.20 |
DisclosureSEC source: 0001140361-22-038694 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,354 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| September 23, 2022 Filed Sep 27, 2022 23:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 1,741 | $3.07 | $5,344.87 |
DisclosureSEC source: 0001140361-22-034883 · form4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,942 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 23:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 1,652 | $3.71 | $6,128.92 |
DisclosureSEC source: 0000899243-22-029894 · doc4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,683 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| July 25, 2022 Filed Jul 28, 2022 01:02 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 1,686 | $4.33 | $7,300.38 |
DisclosureSEC source: 0000899243-22-026920 · doc4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,335 F1 · kind: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 23:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 1,635 | $4.34 | $7,095.90 |
DisclosureSEC source: 0000899243-22-024241 · doc4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,021 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| June 13, 2022 Filed Jun 22, 2022 01:11 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantStock Option (Right to Buy) · Derivative | 18,253 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001209191-22-038610 · doc4.xml · derivative · entry 1 Kumar Rakhi · CIK 0001856296 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,253 Underlying: Common Stock · 18,253 shares Expires 2032-06-12 F1 · derivative.exercise_date: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable. Read SEC document |
| May 20, 2022 Filed May 24, 2022 23:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 12,127 | $3.70 | $44,869.90 |
DisclosureSEC source: 0000899243-22-019395 · doc4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,656 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| April 25, 2022 Filed Apr 27, 2022 23:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 703 | $3.84 | $2,699.52 |
DisclosureSEC source: 0000899243-22-015799 · doc4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,783 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| April 20, 2022 Filed Apr 22, 2022 23:29 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantStock Option (Right to Buy) · Derivative | 1,000,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0000899243-22-015523 · doc4.xml · derivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Shares · 1,000,000 shares Expires 2032-04-19 F1 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 22:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 2,077 | $4.74 | $9,844.98 |
DisclosureSEC source: 0000899243-22-013165 · doc4.xml · nonDerivative · entry 2 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,486 F3 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 22:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 2,486 | $4.84 | $12,032.24 |
DisclosureSEC source: 0000899243-22-013165 · doc4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,563 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| March 25, 2022 Filed Mar 29, 2022 22:27 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 7,281 | $5.06 | $36,841.86 |
DisclosureSEC source: 0000899243-22-012699 · doc4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,049 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| March 18, 2022 Filed Mar 23, 2022 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 2,153 | $5.13 | $11,044.89 |
DisclosureSEC source: 0000899243-22-011864 · doc4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,330 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| March 07, 2022 Filed Mar 10, 2022 02:45 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 3,091 | $5.52 | $17,062.32 |
DisclosureSEC source: 0000899243-22-010364 · doc4.xml · nonDerivative · entry 1 Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,483 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4 Read SEC document |
| April 21, 2021 Filed Oct 8, 2021 22:16 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantStock Option (Right to Buy) · Derivative | 21,698 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-060105 · doc4.xml · derivative · entry 1 Kumar Rakhi · CIK 0001856296 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,698 Underlying: Common Stock · 21,698 shares Expires 2031-04-20 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest in equal monthly installments commencing May 21, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.